All India Institute of Medical Sciences

Researchers

• AGAditya Kumar Gupta
• MMMayank Mishra

Running trials

• Not yet recruiting

  Metformin in Acute Ischemic Stroke

  NCT07899307· Phase 3· All India Institute of Medical Sciences· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Not yet recruiting

  Efficacy of Low Glycemic Index Diet vs Modified Atkins Diet and Gluten Free Casein Free Diet as add-on Therapy With Standard of Care in Children With Autism Spectrum Disorder

  NCT07797725· All India Institute of Medical Sciences· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk

  NCT07553598· All India Institute of Medical Sciences· Source

• Recruiting

  A Study of TAK-755 in Adults With Acute Ischemic Stroke

  NCT07392450· Phase 2· Takeda· Source

• Recruiting

  AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  NCT07571109· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  NCT07571005· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

  NCT07243704· Phase 3· Christian Medical College and Hospital, Ludhiana, India· Source

• Not yet recruiting

  Affordable Made-in-India Microspheres for Liver Cancer Therapy

  NCT07436988· Phase 1· Post Graduate Institute of Medical Education and Research, Chandigarh· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

  NCT07282743· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients

  NCT04480619· Phase 1/2· Advanced Imaging Projects, LLC· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

  NCT07141004· Phase 4· Johnson & Johnson Private Limited· Source

• Recruiting

  Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

  NCT07044687· Phase 4· AbbVie· Source

• Active, not recruiting

  A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

  NCT07030517· Phase 4· Johnson & Johnson Private Limited· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)

  NCT06997367· Phase 2· Bharat Biotech International Limited· Source

• Recruiting

  A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Ulcerative Colitis

  NCT06895252· All India Institute of Medical Sciences· Source

• Recruiting

  A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Crohn Disease

  NCT06890650· All India Institute of Medical Sciences· Source

• Recruiting

  A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies

  NCT06890637· All India Institute of Medical Sciences· Source

• Recruiting

  A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies

  NCT06906445· All India Institute of Medical Sciences· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

  NCT06878404· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Pfizer· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

  NCT06421636· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Effect of Yoga in Chronic Insomnia

  NCT07419152· All India Institute of Medical Sciences· Source

• Enrolling by invitation

  Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease

  NCT07452744· Bioagile Therapeutics Pvt. Ltd.· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

  NCT06305754· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

  NCT06394232· Phase 1/2· Eyestem Research Pvt. Ltd.· Source

• Recruiting

  Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation

  NCT06323330· All India Institute of Medical Sciences· Source

• Active, not recruiting

  Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome

  NCT06256432· Phase 2· Noorik Biopharmaceuticals AG· Source

• Not yet recruiting

  Lesioning Procedures for Movement Disorders

  NCT06352268· All India Institute of Medical Sciences· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 75.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Stroke5 recruiting
• Obesity4 recruiting
• Ulcerative colitis4 recruiting
• Crohn's disease3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Obstructive sleep apnoea3 recruiting
• COPD2 recruiting
• Dystonia2 recruiting
• Metastatic breast cancer2 recruiting
• Sickle cell disease2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Asthma1 recruiting
• Autism1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Essential tremor1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Insomnia1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Completed

  Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam

  NCT06843473· Novo Nordisk A/S· Source

• Completed

  Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial

  NCT06249776· Gravity Medical Technology, INC· Source

• Recruiting

  A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

  NCT05953584· Phase 2· Forma Therapeutics, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Withdrawn

  A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

  NCT05128344· Phase 3· Amzell· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

  NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Terminated

  A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

  NCT05607199· Phase 1· Aurigene Discovery Technologies Limited· Source

• Completed

  Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India

  NCT05683301· Phase 4· Centre for Chronic Disease Control, India· Source

• Completed

  A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

  NCT05375929· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Eli Lilly and Company· Source

• Completed

  Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

  NCT05059327· Phase 2· Noema Pharma AG· Source

• Completed

  A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

  NCT04804540· Phase 4· Takeda· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  Efficacy of Smartphone Based Digital Application in Improving Headache Related Parameters in Patients With Migraine

  NCT04984720· All India Institute of Medical Sciences· Source

• Completed

  A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

  NCT04596631· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  Preventing Adverse Cardiac Events in COPD

  NCT03917914· Phase 3· The George Institute· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

  NCT03715205· Phase 4· Merck Sharp & Dohme LLC· Source

• Completed

  Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

  NCT03606408· Phase 2· RECORDATI GROUP· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

  NCT03573960· Phase 4· Eisai Pharmaceuticals India Pvt. Ltd· Source

• Completed

  RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

  NCT03118986· Phase 2· The Hospital for Sick Children· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Prospective Multi-centre Outcomes Study of Persona Knee System in Total Knee Arthroplasty

  NCT04461626· Zimmer Biomet· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Tuberculosis177 works · 1 trial
• Obesity144 works · 5 trials
• Stroke131 works · 7 trials
• Type 2 diabetes97 works · 7 trials
• Epilepsy78 works · 1 trial
• Glaucoma74 works · 0 trials
• Sarcoma61 works · 1 trial
• Cervical cancer53 works · 0 trials
• Coronary artery disease51 works · 2 trials
• Parkinson disease50 works · 1 trial
• Chronic kidney disease47 works · 2 trials
• Diabetic eye disease36 works · 1 trial
• Ovarian cancer36 works · 1 trial
• Sarcoidosis31 works · 0 trials
• Crohn's disease31 works · 6 trials
• Ulcerative colitis30 works · 10 trials
• Glioblastoma30 works · 0 trials
• Acute myeloid leukaemia30 works · 3 trials
• Head and neck cancer28 works · 2 trials
• Acute lymphoblastic leukaemia28 works · 0 trials
• Multiple myeloma27 works · 1 trial
• Hodgkin lymphoma26 works · 0 trials
• Childhood cancers26 works · 2 trials
• Obstructive sleep apnoea25 works · 3 trials
• Fatty liver disease (MASLD/MASH)25 works · 4 trials
• Congenital heart disease24 works · 0 trials
• Dystonia24 works · 2 trials
• Triple-negative breast cancer24 works · 1 trial
• Hearing loss24 works · 0 trials
• Lupus (SLE)22 works · 1 trial